|
Market Closed -
Other stock markets
|
After hours 20:58:01 | |||
| 4.946 EUR | -0.88% |
|
4.954 | +0.16% |
| 06-30 | Evotec Expands Prefabricated Drug Manufacturing Offerings | MT |
| 06-30 | Just ? Evotec Biologics Launches J.TRAIN Turnkey Continuous Manufacturing Platform For Biologics | CI |
Business description: Evotec SE
Number of employees: 4,526
Sales by Activity: Evotec SE
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Discovery and Preclinical Development | - | - | - | 612M | 529M |
Just - Evotec Biologics | - | - | - | 187M | 260M |
EVT Innovate | 147M | 205M | 267M | - | - |
EVT Execute | 610M | 736M | 739M | - | - |
Intersegment Elimination | -139M | -189M | -224M | -1.21M | -496K |
Geographical breakdown of sales: Evotec SE
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
USA | - | - | 459M | 446M | 432M |
Switzerland | - | - | 64.92M | 109M | 162M |
Rest of the World | - | - | 95.15M | 82.28M | 77.08M |
United Kingdom | - | - | 86.37M | 92.52M | 61.72M |
Germany | - | - | 34.13M | 32.9M | 25.29M |
France | - | - | 32M | 19.91M | 19.86M |
Unallocated | - | - | - | 14.45M | 11.29M |
Executive Committee: Evotec SE
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 30/06/2024 | |
| Director of Finance/CFO | - | 30/04/2026 | |
Ingrid Müller
COO | Chief Operating Officer | - | 30/04/2026 |
Cord Dohrmann
CTO | Chief Tech/Sci/R&D Officer | 62 | 31/08/2010 |
Sarah Fakih
IRC | Investor Relations Contact | - | 31/12/2025 |
Composition of the Board of Directors: Evotec SE
| Director | Title | Age | Since |
|---|---|---|---|
Roland Sackers
BRD | Director/Board Member | 58 | 18/06/2019 |
| Director/Board Member | 64 | 31/05/2021 | |
| Director/Board Member | 43 | 21/06/2022 | |
Duncan McHale
BRD | Director/Board Member | 59 | 09/06/2024 |
Wesley Wheeler
BRD | Director/Board Member | 70 | 09/06/2024 |
Dieter Weinand
CHM | Chairman | 65 | 10/06/2026 |
Wolfgang Hofmann
BRD | Director/Board Member | - | 10/06/2026 |
Company details: Evotec SE
Group companies: Evotec SE
| Name | Category and Sector |
|---|---|
Evotec (France) SAS
 Evotec (France) SAS Miscellaneous Commercial ServicesCommercial Services Engages in research and development of physical and natural sciences |
Miscellaneous Commercial Services
|
Evotec (UK) Ltd.
 Evotec (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development on natural sciences and engineering |
Miscellaneous Commercial Services
|
Evotec International GmbH
 Evotec International GmbH Miscellaneous Commercial ServicesCommercial Services Develops and provides drugs specializing in the treatment of CNS disorders |
Miscellaneous Commercial Services
|
Aptuit (Verona) Srl
 Aptuit (Verona) Srl Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs and medicines |
Pharmaceuticals: Major
|
Other Biotechnology & Medical Research
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.88% | -3.77% | -31.31% | -75.74% | 1.01B | |
| +0.58% | +2.06% | +2.92% | +10.86% | 50.44B | |
| -2.37% | -1.34% | +386.86% | +588.86% | 40.63B | |
| -0.41% | +0.50% | +25.05% | -5.67% | 34.88B | |
| -1.66% | -3.39% | +17.99% | +55.29% | 33.67B | |
| +1.21% | -0.79% | +4.46% | +35.18% | 26.29B | |
| -1.88% | +1.15% | - | - | 17.11B | |
| +0.54% | -4.63% | +64.18% | +122.89% | 15.29B | |
| -9.27% | -29.97% | +37.46% | +39.43% | 10.62B | |
| +0.23% | -0.26% | +15.51% | +21.54% | 13.74B | |
| Average | -1.30% | -2.21% | +58.12% | +88.07% | 24.37B | |
| Weighted average by Cap. | -0.82% | -0.04% | +83.96% | +130.55% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EVT Stock
- Company Evotec SE
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition